LYMPHOMA, MANTLE-CELL
Clinical trials for LYMPHOMA, MANTLE-CELL explained in plain language.
Never miss a new study
Get alerted when new LYMPHOMA, MANTLE-CELL trials appear
Sign up with your email to follow new studies for LYMPHOMA, MANTLE-CELL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat blood cancer patients
Disease control CompletedThis study provided continued access to treatment for people with mantle cell lymphoma that had returned or stopped responding to previous therapies. It compared a combination of ibrutinib and rituximab against other standard drug combinations chosen by doctors. The main goal was…
Matched conditions: LYMPHOMA, MANTLE-CELL
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New hope for Tough-to-Treat lymphoma in elderly patients
Disease control CompletedThis study tested whether adding a newer drug called venetoclax to standard chemotherapy could better control a difficult form of blood cancer called mantle cell lymphoma in older, high-risk patients. It involved 141 patients aged 65 and older who had not received prior treatment…
Matched conditions: LYMPHOMA, MANTLE-CELL
Phase: PHASE2 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
New pill shows promise for Tough-to-Treat blood cancers
Disease control CompletedThis study tested an oral medication called LOXO-305 in Chinese adults with certain types of lymphoma or chronic leukemia that had returned or stopped responding to standard treatments. The main goal was to see how safe the drug was and how well it worked to control the cancer. R…
Matched conditions: LYMPHOMA, MANTLE-CELL
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Mar 13, 2026 15:05 UTC